Jafron Biomedical (300529.SZ) released its 2024 interim performance forecast. It is expected that the net income attributable to the shareholders of the listed company will be between 0.527 billion yuan and 0.583 billion yuan, a year-on-year growth of 90% to 110%; the net income after deducting non-recurring gains and losses will be between 0.501 billion yuan and 0.557 billion yuan, a year-on-year growth of 91% to 112%.
健帆生物(300529.SZ)发预增，预计上半年净利润5.27亿元到5.83亿元，同比增长90%到110%
Jafron Biomedical (300529.SZ) releases pre-increase announcement, with an expected net income of 0.527 billion yuan to 0.583 billion yuan in the first half of the year, a year-on-year growth of 90% to 110%.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.